Excessive angiogenesis associated with psoriasis as a cause for cardiovascular ischaemia.
Psoriasis, a common disease affecting 2%-3% of the UK population, produces significant impairment of quality of life and is an immense burden on sufferers and their families. Psoriasis is associated with significant cardiovascular comorbidity and the metabolic syndrome. Angiogenesis, a relatively under-researched component of psoriasis, is a key factor in pathogenesis of psoriasis and also contributes to the development of atherosclerosis. Vascular endothelial growth factor (VEGF) is a well-established mediator of pathological angiogenesis which is upregulated in psoriasis. It is possible that, in patients with psoriasis, cutaneous angiogenesis may be both a marker for systemic vascular pathology and a novel therapeutic target. In this viewpoint study, the role of VEGF-mediated angiogenesis as a cause for cardiovascular events in patients with psoriasis is explored.
Manchester Academic Health Science Centre, Department of Dermatology, The University of Manchester, Manchester, UK.
Nina
N
Malecic
Manchester Academic Health Science Centre, Department of Dermatology, The University of Manchester, Manchester, UK.
Helen S
0000-0003-1538-445X
HS
Young
D000818:Animals; D050197:Atherosclerosis / Q000378:metabolism / Q000503:physiopathology*; D006801:Humans; D009389:Neovascularization, Pathologic; D011565:Psoriasis / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*; D015398:Signal Transduction; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism*
D042461:Vascular Endothelial Growth Factor A
angiogenesis; atherosclerosis; cardiovascular disease; psoriasis; vascular endothelial growth factor